Genomtec S.A.

Capital/Financing Update • Dec 13, 2022

Completion of the Company's financing phase and conclusion of loanagreements

The ManagementBoard of Genomtec S.A._#160;based in Wrocław (_quot;Issuer_quot;, _quot;Company_quot;;_quot;Borrower_quot;) announces that on 13 December 2022 it finalised thefinancing stage of the Company by completing the process of concludingloan agreements with the right to acquire the Company's shares withnatural persons and legal entities (_quot;Lenders_quot;), including today (13December 2022) the Issuer concluded with a legal entity based in Polandtwo loan agreements with the right to acquire the Company's shares for atotal amount of PLN 2.9 million The remaining agreements were concludedfor smaller amounts not exceeding PLN 400,000.

Under theaforementioned agreements, the Company raised a total of PLN 4.4 millionto improve its cash position and implement the Company's future strategy.Loanscan be repaid as follows:(i) cash repayment due by 31December 2023, with the repayment term reserved in favour of theBorrower, i.e. the Borrower has the right to repay part or all of theLoans early,(ii) subscription of the Borrower's new issue sharesby the Lenders (the _quot;Share Subscription Right_quot;). Repayment of the Loanby way of the Share Subscription Right is a right of the Borrower, i.e.the Company has the right to repay the Loan by way of the ShareSubscription Right and, in the event that the Borrower makes adeclaration to exercise this right, the Borrower and the Lendersundertake to carry out the repayment by way of the Share SubscriptionRight. Under the Share Subscription Right, the Borrowers shall beentitled to subscribe for such number of shares in the Company as shallbe calculated as the quotient of: (a) the amount of the Loan paid andnot repaid, together with the interest due, and (b) the issue price ofPLN 5.00 (five zlotys), which has been determined as the average priceof the Issuer's shares on the NewConnect market weighted by tradingvolume for the last 3 months calculated as at the date of the LoanAgreement, less a discount of not more than 10%.The provision offunds to support the implementation of the Company's announced strategyis a material event for the Company's business and, in the opinion ofthe Board of Directors, meets the criteria for confidential informationwithin the meaning of Article 17(1) MAR.